Status:
COMPLETED
Effect of Abrupt Plavix® Discontinuation on Platelet Function
Lead Sponsor:
Université de Montréal
Collaborating Sponsors:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Brief Summary
The well established importance of regular administration of antiplatelet drugs stands on firm grounds, as large meta-analyses have shown these therapies to significantly reduce the risk of death. Pla...
Eligibility Criteria
Inclusion
- Group 1: Patients suffering from stable CAD scheduled to discontinue clopidogrel therapy at least one month after stent implantation
- Group 2: Stable clopidogrel-naïve CAD patients
- Patients willing to participate in the study and to sign the informed consent form
Exclusion
- Acute coronary syndrome or revascularization in the last 3 months prior to enrolment
- Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), ticlopidine, dipyridamole, warfarin or acenocoumarol
- Major surgical procedure within 1 month before enrolment
- Platelet count outside the 100 000 to 450 000/μL range
- Hematocrit \< 25% or haemoglobin \< 100 g/L
- Patient undergoing dialysis for chronic renal failure
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00670943
Start Date
January 1 2008
End Date
March 1 2009
Last Update
March 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada, H4J 1C5